Recent Updates
Recently added Catalysts
BLRX Positive Sentiment

BioLineRx to Report Third Quarter 2026 Results on November 23, 2026

Key Takeaway: BioLineRx Ltd. will announce its third quarter 2026 financial results on November 23, 2026. The announcement will be followed by a conference call at 8:30 a.m. EST, led by CEO Philip Serlin. The company is advancing its lead asset, GLIX1, in clinical trials for glioblastoma and solid tumors.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioLineRx is set to report Q3 results soon.
  • The company is developing promising therapies in oncology.
  • GLIX1 is in Phase 1/2a trials targeting glioblastoma.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+256%
120-day peak, hindsight
Typical move
6.8%
average across 3 past catalysts
Lead asset
horse anti-thymocyte globulin
Phase 2 · Aplastic Anemia

Full Press Release Details

Management to Hold Conference Call at 8:30 a.m. EST
TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2026 on Monday, November 23, 2026, before the U.S. markets open.
The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 25, 2026; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

Frequently Asked Questions

When will BioLineRx report its Q3 2026 results?

BioLineRx will report its Q3 2026 results on November 23, 2026.

What time is the conference call for Q3 results?

The conference call will take place at 8:30 a.m. EST.

Who will lead the conference call?

The call will be led by CEO Philip Serlin.

What is BioLineRx's lead development asset?

BioLineRx's lead asset is GLIX1, targeting glioblastoma.

Last updated: Nov 18, 2026